Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isradipine
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Isradipine is a dihydropyridine calcium channel blocker used primarily to treat high blood pressure (hypertension). It works by inhibiting the influx of calcium ions through L-type calcium channels in cardiac and arterial smooth muscle cells, leading to relaxation of blood vessels (vasodilation), reduced systemic vascular resistance, and decreased workload on the heart. Isradipine exhibits greater selectivity for arterial smooth muscle compared to cardiac tissue. It has also been investigated for neuroprotective effects in Parkinson’s disease but failed to show efficacy in phase 3 clinical trials. Isradipine is available as an oral capsule and may be used alone or with other antihypertensive agents such as diuretics.
- Brand names
- DynaCircDynaCirc CR
- Other names
- Isradipine GITS
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D)
Beyond the preview
Go deeper on Isradipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Isradipine.